InvestorsHub Logo

H2R

Followers 41
Posts 2214
Boards Moderated 0
Alias Born 07/17/2014

H2R

Re: None

Saturday, 08/07/2021 10:20:53 AM

Saturday, August 07, 2021 10:20:53 AM

Post# of 12138

a record 561 clinical trials, compared with 543 at the end of the first quarter of 2021 and 491 at the end of the second quarter of 2020,

and eight commercial therapies in regenerative medicine, including SKYSONA™, a one-time gene therapy for the treatment of early cerebral adrenoleukodystrophy (CALD) by bluebird bio, which was granted marketing authorization by the European Commission on July 21, 2021.


http://ir.cryoport.com/news-releases/2021/08-05-2021-211017233

Talk about a growth story!
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYRX News